viewAntibe Therapeutics Inc

Antibe Therapeutics to sell units to raise money to further develop lead osteoarthritis drug

Antibe is working on getting the drug ready for an investigational new drug (IND) application, as well as a meeting with the Food and Drug Administration

back pain
ATB-346 drug targets acute and chronic pain associated with osteoarthritis

Antibe Therapeutics Inc (CVE:ATE) (OTCMKTS:ATBPF) announced Tuesday it is proposing to sell units in the company to raise money as it further develops its lead drug, ATB-346.

The drug targets acute and chronic pain associated with osteoarthritis. Its Phase 2B dose-ranging, efficacy study for the drug remains on track, and the company hopes to use the proceeds “to fund certain activities in preparation for planned meetings with regulatory agencies and eventual global partnering discussions” once the study ends.

Antibe is working on getting the drug ready for an investigational new drug (IND) application, as well as a end-of-Phase-2 meeting with the US Food and Drug Administration.

READ: Antibe Therapeutics hosts successful annual and special general meeting

The preparation is intense, requiring comprehensive data packages encompassing pharmacokinetics, metabolism, toxicology, chemistry and manufacturing, among other factors.

Antibe has proposed an offering price of C$0.30 per unit, and each unit will be comprised of one common share and one-half of one common share purchase warrant. Antibe shares were halted pending the news, having dropped by 3% to C$0.30.

The Toronto-based company said the total size of the offering “will be determined in the context of the market at the time of entering into an agency agreement for the offering.”

Each warrant will entitle the holder to purchase one common share at an exercise price of $0.40 for a period of 36 months following the closing date of the offering.

The offering will be made in British Columbia, Alberta, Saskatchewan, Manitoba and Ontario, and the company expects to grant a 30-day over-allotment option to sell up to an additional 15% of the number of units and/or warrants offered.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Antibe Therapeutics Inc

Price: 0.69 CAD

Market: TSX-V
Market Cap: $194.09 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...



Full interview: Antibe Therapeutics finishes Phase 2 trial for ATB-346;...

Antibe Therapeutics (CVE: ATE OTCQB: ATBPF) CEO Dan Legault joined Steve Darling from Proactive Vancouver to share details about how the company is dealing with the Pandemic crisis and if they are seeing any effect on their Phase 2 study with their lead drug, ATB-346. Legault also told Proactive...

on 7/4/20

2 min read